Win a Grant to the C3 in Orlando, Florida

Participe por una beca para asistir al C3 en Orlando, FloridaFrom June 27th to June 30th, Orlando, Florida will hold the Complex Cardiovascular Catheter Therapeutics (C3 Conference), an event with a steadily growing number of attendees each year.

 

The Conference Organizing Committee grants, through SOLACI, five scholarships for professionals aiming to present their approved work or complex case.

 

Scholarships include the following:

  • Congress registration fee.
  • Three nights lodging for the aforementioned date.
  • Plane tickets through the Congress official travel agency (with a maximum limit of USD 1000).

 

 

How can you submit your work? 

Cases shall be submitted through the following form:

Enter 
(Spanish form)

 

Your presentation must fulfill the following requirements:

    • Submit a “.doc” or “.docx” file with the description of the case to be presented. The text must be up to 300 words long, in an 11 pt font.

 

    • Submit a supplementary “.ppt” or “.pptx” file with the case presentation. While videos (up to 5) will be admitted for use during the oral presentation, this initial file can only include up to 5 fixed images.

 

    • Case and description must be submitted in english.
  •  
    • Presenters can submit more than one case. In such a circumstance, they shall make different submissions, one for each presentation.
 

Submission deadline: March 30th, 2018.

 

C3 is a Congress designed for physicians who specialize in interventional cardiology, vascular surgery, and interventional radiology, as well as fellows, residents, and other healthcare professionals interested in atherosclerotic cardiovascular disease. C3 offers presentations and debates with expert global faculty, live and pre-recorded cases, industry-sponsored and supported symposia, exhibit booths and simulators, poster sessions, case presentations and hands-on workshops.

 

Learn more www.c3conference.net


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

 

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Check out the best images of the El Salvador 2024 Sessions

Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....